Leerink Partnrs Has Optimistic Outlook of Insmed Q2 Earnings

Insmed, Inc. (NASDAQ:INSM) – Equities research analysts at Leerink Partnrs upped their Q2 2026 earnings per share (EPS) estimates for Insmed in a note issued to investors on Tuesday, November 18th. Leerink Partnrs analyst J. Schwartz now anticipates that the biopharmaceutical company will earn ($1.06) per share for the quarter, up from their previous estimate of ($1.07). The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share. Leerink Partnrs also issued estimates for Insmed’s Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.79) EPS and FY2027 earnings at ($2.46) EPS.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The company had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business’s revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.27) earnings per share. Insmed has set its FY 2025 guidance at EPS.

Several other research firms also recently issued reports on INSM. Cantor Fitzgerald began coverage on Insmed in a report on Tuesday, October 28th. They set an “overweight” rating and a $192.00 price objective on the stock. Bank of America raised their target price on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Stifel Nicolaus lifted their target price on shares of Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 14th. William Blair assumed coverage on shares of Insmed in a research report on Wednesday, August 20th. They issued an “outperform” rating for the company. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average target price of $175.53.

Insmed Trading Down 1.9%

Shares of NASDAQ INSM opened at $199.64 on Friday. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed has a 12 month low of $60.40 and a 12 month high of $208.00. The company has a market cap of $42.58 billion, a price-to-earnings ratio of -34.96 and a beta of 1.05. The business has a fifty day simple moving average of $166.68 and a 200-day simple moving average of $123.91.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Kingsview Wealth Management LLC raised its holdings in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 60 shares in the last quarter. Choreo LLC grew its stake in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares in the last quarter. Spire Wealth Management grew its stake in Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 80 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its position in Insmed by 59.6% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares during the last quarter. Finally, Moody Aldrich Partners LLC increased its position in Insmed by 2.4% in the 3rd quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock worth $799,000 after purchasing an additional 132 shares during the last quarter.

Insider Buying and Selling

In related news, Director Elizabeth M. Anderson sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the transaction, the director directly owned 63,729 shares of the company’s stock, valued at approximately $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the completion of the sale, the director owned 262,675 shares of the company’s stock, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 252,922 shares of company stock worth $43,533,383 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.